

JUL - 7 1997

SMDA Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Description: The Doyle Combo Nasal Airway Splint is designed to provide septal support and allow nasal breathing post-operatively through the integral airway. The patented design features an expandable PVA sponge layer for added comfort and stabilization. For additional security, the splints can be sutured through the pre-formed holes in the anterior tips. The Doyle Combo Nasal Airway Splints are packaged as a pair (left side and right side) and are supplied sterile, ready to use.

Indication For Use: To maintain a nasal airway while providing septal support following surgery.

Contraindications: None known.

0.

Predicate Device: Product No. 20-10500 manufactured by Invotec International, Inc., 11243-1 St. John's Industrial Parkway South, Jacksonville, FL 32246, and Product No. Q601318 manufactured by M-Pact, 1040 OCL Parkway, Eudora, KS 66025.

Testing: Device is constructed using well-established medical grade silicone and PVA sponge.

Submitted by:	1/10/1/1/hm, PHESINENT		
	Stuart K. Montgomery, President		
Date:	6/3/97		



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Stuart K. Montgomery President Boston Medical Products 117 Flanders Road Westborough, MA 01581

JUL - 7 1997

Re: K972151

Doyle Combo Nasal Airway Splint

Dated: June 26, 1997 Received: July 1, 1997

Unclassified/Procode: 77 LYA

Dear Mr. Montgomery:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Lillian Yin, Ph.D.

Director, Division of Reproductive,

Abdominal, Ear, Nose and Throat,

and Radiological Devices
Office of Device Evaluation

Center for Devices and

Radiological Health

Boston Medical Products, Inc. 117 Flanders Road Westborough, MA 01581 ATT: Stuart K. Montgomery (508) 898-9300 ext. 240

Page 1 of 1

51	O(k)	Number	(if	known):
\cdot	~(,	, , , , , , , , , , , , , , , , , , , ,	(

Device Name:

Doyle Combo Nasal Airway Splint

Indications For Use:

To maintain a nasal airway while providing septal support following

surgery.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE	IF NEEDED)
---	------------

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Uses (Per 21 CFR 801.109) OR

Over-The-Counter Use__

(Optional Format 1-2-96)

(Division Sign-Off)

Division of Reproductive, Aprilominal, ENT,

and Radiological Devices

510(k) Number_